Skinbiotherapeutics Share Discussion Threads

[onedayrodders] 06/6/2017 16:55

Investor shows and seminars etc as we have seen with OPTI for a year or so, do not impact the share price to any degree or sustainability.

Apart from direct RNS news the near term catalyst for upward movement here would be if OPTI announce multiple deals over the next few weeks and months, SOH has strongly hinted at the same and some very lucrative (£5m deals possible)

That will provide a boost here as the science will be finally proven through the serious commercialization.

A few more weeks of nothing here and it's sub 10p again. That's AIM.

[aim_trader] 06/6/2017 14:27

SkinBio Therapeutics will be presenting to investors at the upcoming Proactive One2One Forum taking place on the evening of 15th June. For details and registration, please click here:

[onedayrodders] 06/6/2017 12:33

There is no way these disruptive technology stocks can just sit at a level inbetween newsflow when no revenue is in place to sustain.

Too many lottery type investors looking for the next overnight winning ticket.
10 mins is seen as long term by the majority AIM retail plonkers.

[judijudi] 06/6/2017 09:29

Top call that was Trotts :(

[ibug] 02/6/2017 09:56

SBTX research into skin bacteria is going to have some spin offs imo:

About 85% of people get acne at some point in their lives, and scientists have long blamed it on the bacterium Propionibacterium acnes. But so-called P. acnes never entirely explained acne, because research has shown that it's abundant in hair follicles of people with clear skin, too—not just those with pimples.

Now, new research puts forth a different potential acne culprit: an imbalance of bacteria living on the skin. The findings, presented recently at the Microbiology Society’s Annual conference and published in the journal Scientific Reports, suggest that balancing bacteria—not wiping it out, as antibiotic treatments do—may be one future way to battle breakouts.

[trotterstrading] 31/5/2017 10:59

Sellers dried up, nice base formed ready for the move higher :0)

[parob] 30/5/2017 12:28

Doesn't seem to be going any lower. Perhaps this is the higher low going in...

[parob] 27/5/2017 11:09

SkinBioTherapeutics Plc (LON:SBTX) CEO Dr Catherine O’Neill talks to DirectorsTalk about the extension of a contract with the University of Manchester. Catherine explains the purpose and audience of SkinBiotix, how the company will benefit from the extension of the research contract, the importance of being labelled ‘dermatologically tested’ and what investors should be looking out for in terms of news flow.

[parob] 25/5/2017 15:06

You're welcome John. If this drops to 12p to buy I'm taking a few more.

[humphries1] 25/5/2017 12:47

its safe, no bomb

[2350220] 25/5/2017 12:17

Haven't seen anything about that on the news,
John

[wreckage] 25/5/2017 11:17

This could be worrying... newsflash .. BOMB UNIT SENT TO MANCHESTER COLLEGE

No further information

[parob] 25/5/2017 01:03

IS BACTERIA THE SECRET TO YOUR BEST SKIN EVER?

GOOD LOOKS
RACHEL LAPIDOS, MAY 24, 2017



SBTX is in the right space.

[ibug] 23/5/2017 18:14

Here is a very interesting key message from that business plan presentation:

“Our business strategy is we out-license to our partners very early on; to companies that are much bigger than us that can go on and commercialise our products for us,” said O’Neill.

“So, we have inflexion points in the near-, medium- and long-term for markets that are absolutely huge.”

[ibug] 23/5/2017 16:04

new article with some analysis ---



SkinBiotherapeutics: New listing in the emerging field of the human microbiome has multiple value trigger points 13:15 23 May 2017

The company is based around the research on the skin microbiome by chief executive Dr Cath O’Neill and her team at Manchester University.

Eczema - The company is working on a treatment for the condition, a programme chief executive Cath O'Neill says is close to her heart

Doctor Michael Mosley, author of the hugely popular 5:2 Diet, has been quick to seize onto research into the human microbiome, which forms the centre-piece to his latest weight loss book.

For the uninitiated, the microbiome is found in the gut and on the skin. It consists of 10,000 microbial species and some 8mln protein encoding genes.

What we are beginning to learn is this eco-system, a microbial genome if you will, affects immunity, cognitive heath and the metabolism.

Mosley’s latest paperback is focused on the gut. One of the industry pathfinders in the field is London-listed OptiBiotix, led by the irrepressible Stephen O’Hara.

Spun out of OptiBiotix last month was SkinBioTherapeutics PLC (LON:SBTX), based around the research on the skin microbiome by chief executive Dr Cath O’Neill and her team at Manchester University.

As part of the separate listing the company raised £4.5mln, which will be invested in developing a cosmetic for sensitive skin, an anti-infective hand product and potential treatment for eczema.

It is fair to say the research to date on the human microbiome has tended to focus on the gut rather than the skin, although there has been a significant uptick in work on the latter recently, according to life sciences investor Seventure Partners.

SkinBio has developed a topical probiotic, though cream applied to skin isn’t live in the way the popular health-enhancing drinks and yoghurts are.

Its SkinBiotix platform is protected by three patent families and 18 patent applications and is supported by a host of peer-reviewed academic publications.

Founded on science

“This company is founded on absolutely sound science and that’s important to me,” CEO O’Neill told Proactive Investors.

That platform technology has been developed to enhance the skin cell barrier, protect the skin and aid its regeneration.

From that it is developing the three products that manage, protect and restore the body’s largest organ.

The platform has also provided the company with near-, medium- and long-term “value inflection points”, according to O’Neill.

First cab off the rank will be the company’s cosmetic for sensitive skin, which should be properly formulated towards the end of this year, before entering human studies in the second-quarter of next.

The idea would be to compile a product information file, or PIF, that contains safety and information data, said O’Neill.

The plan then would be to find a partner who, very early in the piece, takes the product into the commercial phase.

“We’ve had early conversations about the cosmetic and we are getting nice positive feedback, so we are hopeful,” said the SkinBio boss.

Hospital infection

Going into development in the third-quarter of next year is a prophylactic for healthcare acquired infections.

The proliferation of dispensers at the doors to wards is designed to prevent the rampant spread of hospital-acquired illnesses.

The problem is the alcohol-infused gel plays havoc with the hands of frequent users, such as doctors and nurses, and as such there is an unmet need for a more skin-friendly protective.

It is worth at this juncture pointing out that SkinBio’s products are tapping into huge potential markets – cosmetics is worth an estimated US$100bn a year, infection prevention US$17bn and eczema US$3.9bn.

The company hopes to begin commercialising the protective hand cream in 2020, the same year as development work begins on the eczema treatment.

Proof of concept human studies are likely to begin on the latter in 2021, with a partner coming on board by 2022 at the latest.

“The eczema programme is more complicated as it will involve phased trials,” said O’Neill.

“We want to be in the position where we have the regulatory pack. There are a lot of things you have to do before you can go into a human disease trial.”

Well funded

As mentioned above, the stock market listing saw the company raise £4.5mln of investment, which means it is funded out to the end of 2018, at which point it should have a commercial partner for the cosmetic product.

Successfully achieving this milestone should result in a valuation uplift, which in turn would allow SkinBio to go out and refill the coffers.

Debuting at 9p, the stock hasn’t done too badly over the last six weeks, touching 13.5p earlier this month, before settling at 12.85p.

For the founding AIM investors that’s a 54% boost to the value of their holdings.

However, you sense this is just the first page of the first chapter of what looks set to be an interesting and exciting adventure.

“Our business strategy is we out-license to our partners very early on; to companies that are much bigger than us that can go on and commercialise our products for us,” said O’Neill.

“So, we have inflexion points in the near-, medium- and long-term for markets that are absolutely huge.”

www.proactiveinvestors.co.uk/companies/news/178204

[luminoso] 23/5/2017 15:57

Galashiels, I found your post helpful and Not aimed at this stock but at informing people. Certainly suffered in the past from one or two of that list. Cheers.

[ibug] 23/5/2017 12:22

More news making the rounds:

SkinBioTherapeutics Secures Extension With University Of Manchester Tue, 23rd May 2017 12:54

LONDON (Alliance News) - SkinBioTherapeutics PLC on Tuesday said it has secured an eight-month extension to its research contract with the University of Manchester, prolonging the contract until June 2018.

The life science company focused on skin health said the extension includes a provision for the appointment of a second technician, which it said will increase the company's ability to develop its SkinBiotix platform.

Furthermore, the company said it has recently demonstrated activity of SkinBiotix at a range of doses in human skin models, and also completed the design of two human safety trials. If successful, these trials will allow the technology to be labelled 'dermatologically tested' for its cosmetic application, the company said.

"We are making progress in our research, and the extension and expansion of our contract with the University of Manchester will allow meaningful progression across the company. We are pleased with the progress of SkinBiotix, and are confident that it remains on track," said Chief Executive Catherine O'Neill.

"As a team, we have nurtured relationships with industry stakeholders for many years. Since our IPO, we have continued to ensure potential commercial partners are aware of the capabilities of the SkinBiotix platform," she added.

SkinBioTherapeutics shares were down 6.3% on Tuesday at 12.30 pence.

By Joshua Warner; [e-mail]; @JoshAlliance

Copyright 2017 Alliance News Limited. All Rights Reserved.

[galashiels] 23/5/2017 12:00

I am sure SBTX may be a good company, I have not gone deeper into this one yet, my post is in relation to AIM listed companies and potential risk factor of certain brokers and advisors, I personally now avoid any company with any of the above mention companies involved but that is my personal choice based on my experience.

I do get what you are saying re inherent high risk of AIM company but pls do not ignore what I am highlighting.

I do wish you good luck no matter what, no hard feelings.

[slartybartfaster] 23/5/2017 11:25

Galashiels, SBTX is fully funded. Do some research you fool, better still don't invest your JSA in aim companies if that is the sum total of your research.

[ibug] 23/5/2017 10:13

Galashiels 23 May '17 - 10:04 - 393 of 393 0 0 (Filtered)

NOT APPLICABLE TO THIS STOCK imo

[galashiels] 23/5/2017 10:04

AIM Listed:

If these guys are behind any AIM listed company, people should look at the dilution history of that company, in general they may find dilution - consolidation - dilution pattern, no matter how good the company, if you are going to keep getting diluted to keep a company afloat, what's the point, It's you who are feeding money to them, source of income is shareholders.

Cairn Financial Advisers LLP
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=312

WH Ireland Limited
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=101

Hybridan LLP
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=290

Daniel Stewart & Company Plc
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=134

Northland Capital Partners
www.londonstockexchange.com/exchange/companies-and-advisors/aim/for-companies/nomad-broker-profile.html?nomadBrokerId=22

Do go back and check those penny stocks that you may have been diluted out in the past, were these guys behind those companies too?

Feel free to copy this post and post it on any thread that you deem proper to highlight the issue of small investors getting screwed time after time.

[ibug] 23/5/2017 10:03

We are looking at product development this year and commercialization in 2018...looks like the development plan is progressing well imo.

Once the safety certificate has been awarded then clinical trials can start.


Todays news suggests the development plan is rolling out imo.

[onedayrodders] 23/5/2017 09:55

Although I agree it's underwhelming why would you NOT expect similar RNS to OPTI ?!?!

It's the same science ..and it's at a very early stage